Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat Posttraumatic Stress Disorder (PTSD) in Active Duty or Retired Service Members: A Pilot Study
Latest Information Update: 13 Sep 2022
Price :
$35 *
At a glance
- Drugs Ropivacaine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 08 Sep 2022 Status changed from active, no longer recruiting to completed.
- 12 Aug 2021 Planned End Date changed from 1 Jan 2023 to 1 Aug 2022.
- 12 Aug 2021 Planned primary completion date changed from 1 Nov 2022 to 1 Aug 2021.